Intelligence / Healthtech & medtech market map / Clinical and regulatory support services / Clinical evidence and trial services / Pharma and biotech outsourced clinical development
Pharma and biotech outsourced clinical development
Pharmaceutical and biotechnology companies that outsource protocol design, patient and site management, monitoring, data management and regulatory-submission evidence across the clinical development lifecycle, including evidence work used for payer coverage.
- Level
- Niche
- Segmented by
- Customer type
- Buyers
- Pharmaceutical and biotechnology sponsors
- Buying centre
- Clinical development, regulatory affairs, HEOR/market access, procurement
- New clinical programme or protocol launch
- Phase transition or pivotal-study start
- Regulatory-submission deadline
- Payer-coverage evidence request
- Slow patient recruitment and site activation
- Fragmented trial operations and data handoffs
- Incomplete or submission-inconsistent evidence packages
- Insufficient internal capacity to run concurrent studies
How this was sized
$63.6B ($62.6B–$64.7B) · 2025 · Top-down
Annual vendor revenue is estimated as published CRO/clinical-trial services of $57.5-$59.6B plus published medical-writing services of $5.1B, giving $62.6-$64.7B for 2025. The source reports 6.5%-7.5% annual growth for CRO/clinical-trial services and about 10% for medical writing, but no consistent combined forecast horizon; therefore no combined forecast or CAGR is stated. The total covers outsourced clinical development and submission-document services, not the full internal cost of trials.
- Pharma Outsourcing and Software Market Size: CRO, PV, QMS
askdona.com · 2026-10-31
Alongside it in Clinical evidence and trial services
// Sell into Pharma and biotech outsourced clinical development